Weiguang Biotechnology: Intended to sign a 1.13 billion yuan blood product technology cooperation contract.

Weiguang Bios announcement stated that it plans to sign a "Blood Products Technology Cooperation Contract" with its partner, involving the technical license and transfer of some blood products, with a total cost of 16 million US dollars, equivalent to approximately 113 million RMB. The contract includes the production technology license and services for 6 blood product varieties, and allows the use of 4 production bases in the licensed area. The transaction does not constitute a major asset restructuring and is within the approval authority of the board of directors. It is expected that the fulfillment of the contract will have a positive impact on business results, but may be affected by factors such as personnel, facilities, and exchange rates.